Early investigational drugs that target epidermal growth factor receptors for the treatment of head and neck cancer.

Ugurluer G. , Ozsahin M.

Expert opinion on investigational drugs, cilt.23, sa.12, ss.1637-54, 2014 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 23 Konu: 12
  • Basım Tarihi: 2014
  • Doi Numarası: 10.1517/13543784.2014.951435
  • Dergi Adı: Expert opinion on investigational drugs
  • Sayfa Sayıları: ss.1637-54


Introduction: Squamous-cell carcinoma of the head and neck (SCCHN) remains a challenging clinical problem, due to the persistent high rate of local and distant failures and the occurrence of secondary primaries. For locally advanced SCCHN, a combination of chemotherapy (CT), radiation or surgery is often used, but there are limitations, which may reduce compliance. Molecular targeted therapies, namely anti-EGFR treatments, are in development with the aim of improving clinical outcomes and mitigating treatment-related toxicities.